283 related articles for article (PubMed ID: 19451425)
1. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.
Bennouna J; André T; Campion L; Hiret S; Miglianico L; Mineur L; Touchefeu Y; Artru P; Asmis T; Bouché O; Borde F; Kavan P; Lam YH; Rajpar LS; Emile JF; Jouffroy C; Gill S; Taïeb J
Clin Colorectal Cancer; 2019 Mar; 18(1):e69-e73. PubMed ID: 30415988
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
Symonds L; Yu M; Zhang Y; Ou FS; Zemla TJ; Carter K; Bertagnolli M; Innocenti F; Bosch LJ; Meijer GA; Carvalho B; Grady WM; Cohen SA
Epigenetics; 2022 Dec; 17(12):1715-1725. PubMed ID: 35412430
[TBL] [Abstract][Full Text] [Related]
4. Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis.
Kuang Z; Wang J; Liu K; Wu J; Li J
Int J Surg; 2024 May; 110(5):3030-3038. PubMed ID: 38349218
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy of colon cancer: current status and future developments.
Morse MA
Clin Colon Rectal Surg; 2005 Aug; 18(3):224-31. PubMed ID: 20011305
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer.
Bae SB; Lee NS; Kim HJ; Kim KH; Kim HJ; Kim CK; Lee KT; Park SK; Won JH; Hong DS; Park HS
Cancer Res Treat; 2006 Apr; 38(2):72-7. PubMed ID: 19771263
[TBL] [Abstract][Full Text] [Related]
7. First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Legoux JL; Faroux R; Barrière N; Le Malicot K; Tougeron D; Lorgis V; Guerin-Meyer V; Bourgeois V; Malka D; Aparicio T; Baconnier M; Lebrun-Ly V; Egreteau J; Khemissa Akouz F; Terme M; Lepage C; Boige V
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672597
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection.
Huang MY; Huang CM; Tsai HL; Huang CW; Hsieh HM; Yeh YS; Wu JY; Wang WM; Wang JY
Oncol Lett; 2017 Dec; 14(6):6754-6762. PubMed ID: 29163699
[TBL] [Abstract][Full Text] [Related]
9. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
12. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.
Alberts SR; Sargent DJ; Nair S; Mahoney MR; Mooney M; Thibodeau SN; Smyrk TC; Sinicrope FA; Chan E; Gill S; Kahlenberg MS; Shields AF; Quesenberry JT; Webb TA; Farr GH; Pockaj BA; Grothey A; Goldberg RM
JAMA; 2012 Apr; 307(13):1383-93. PubMed ID: 22474202
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Yothers G; O'Connell MJ; Allegra CJ; Kuebler JP; Colangelo LH; Petrelli NJ; Wolmark N
J Clin Oncol; 2011 Oct; 29(28):3768-74. PubMed ID: 21859995
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
Allegra CJ; Yothers G; O'Connell MJ; Sharif S; Petrelli NJ; Colangelo LH; Atkins JN; Seay TE; Fehrenbacher L; Goldberg RM; O'Reilly S; Chu L; Azar CA; Lopa S; Wolmark N
J Clin Oncol; 2011 Jan; 29(1):11-6. PubMed ID: 20940184
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
[TBL] [Abstract][Full Text] [Related]
17. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
